InfuSystem Enters Lymphedema Therapy Market

ROCHESTER HILLS, Michigan (June 29, 2021)—InfuSystem Holdings, Inc., a national health care service provider facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced that it has entered into a joint agreement with Bio Compression Systems, Inc. whereby InfuSystem will add lymphedema therapy to its Integrated Therapy Service (ITS) platform.

As part of the new relationship with Bio Compression Systems, Inc., InfuSystem’s turnkey solutions will include providing pneumatic compression devices with calibrated and non-calibrated gradient pressure, garments and certified technicians for proper fitting of the compression system. Additionally, InfuSystem was recently designated as a Community Health Accreditation Partner to provide pneumatic compression devices for the Lymphedema therapy market.

“We are excited to announce our fourth therapy with the addition of Lymphedema to our ITS platform, joining our existing therapies: oncology, pain management and wound care,” said InfuSystem CEO Richard DiIorio. “With our recent CHAP accreditation, we expect to begin onboarding new customers and treating patients in the next 60 days, with a significant revenue contribution from our new lymphedema therapy in 2022 to 2023. Under the agreement, our team will be providing pneumatic compression devices and associated garments to facilitate outpatient care, initially targeting our acute care and oncology customers and thereby addressing what we estimate to be 20% of the larger multi-billion dollar lymphedema market. We look forward to providing our industry leading patient care and customer service to this new vertical market as we continue to expand our portfolio of home healthcare services, which improve the quality of patient care.”